Quick Answer
InMed Pharmaceuticals Inc. reported Research And Development Expense of $2.85 million for the year ending 2025.
- InMed Pharmaceuticals Inc. showed a decrease of -11.3% in Research And Development Expense from 2024 to 2025.
- This data is from InMed Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), InMed Pharmaceuticals Inc.'s Research And Development Expense has declined by 50.9%.
- Historical annual values: Fiscal year 2025: $2.85 million | Fiscal year 2024: $3.22 million | Fiscal year 2023: $3.73 million | Fiscal year 2022: $7.28 million | Fiscal year 2021: $5.34 million | Fiscal year 2020: $5.81 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: